1
|
Golaszewski NM, LaCroix AZ, Hooker SP, Bartholomew JB. Group exercise membership is associated with forms of social support, exercise identity, and amount of physical activity. Int J Sport Exerc Psychol 2021; 20:630-643. [PMID: 35494549 PMCID: PMC9053316 DOI: 10.1080/1612197x.2021.1891121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 02/09/2021] [Indexed: 06/14/2023]
Abstract
Exploring whether the mechanisms underlying the positive relationship between group exercise and physical activity are forms of social support - emotional, validation, informational, instrumental, and companionship and exercise identity. Participants (n=506; M age = 34.3) completed a 235-item questionnaire assessing physical activity, exercise identity, social support, and other determinants of physical activity. Exploratory path analysis was used to model group exercise membership, forms of social support, exercise identity, and metabolic equivalent (MET) minutes/wk. Women and men had similar yet varying results. For women, group exercise membership was significantly associated with MET-minutes/wk (β = 0.11) and exercise identity (β = 0.17). There was a significant association between exercise identity and MET-minutes/wk (β = 0.38). Women perceived belonging to an exercise group provides emotional (β = 0.36), validation (β = 0.25), informational (β = 0.35), instrumental (β = 0.19), and companionship (β = 0.46) support. Validation (β = 0.11), informational (β = 0.21), and companionship (B = 0.17) were significantly associated with exercise identity for women. For men, group exercise membership was not significantly associated with MET-minutes/wk or exercise identity. Exercise identity was significantly associated with MET-minutes/wk (β = 0.46). Men perceived belonging to their group provides emotional (β = 0.31), validation (β = 0.32), informational (β = 0.33), and companionship (β = 0.34). Validation (β = 0.22), informational (β = 0.30), and emotional (β = 0.23) were significantly associated with exercise identity for men. Belonging to an exercise group is associated with forms of social support that strengthen exercise identity.
Collapse
Affiliation(s)
- N M Golaszewski
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0811
| | - A Z LaCroix
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0811
| | - S P Hooker
- College of Health and Human Services, San Diego State University, San Diego, CA 92182
| | - J B Bartholomew
- Department of Kinesiology and Health Education, The University of Texas at Austin, 2109 San Jacinto Blvd., D3700, Austin, TX 78712-1415
| |
Collapse
|
2
|
Adami G, Saag KG, Mudano AS, Rahn EJ, Wright NC, Outman RC, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Ladores S, Curtis JR, Danila MI. Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. Osteoporos Int 2020; 31:1283-1290. [PMID: 32020264 PMCID: PMC7365553 DOI: 10.1007/s00198-020-05312-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Accepted: 01/22/2020] [Indexed: 02/02/2023]
Abstract
UNLABELLED We investigated the factors associated with readiness for initiating osteoporosis treatment in women at high risk of fracture. We found that women in the contemplative stage were more likely to report previously being told having osteoporosis or osteopenia, acknowledge concern about osteoporosis, and disclose prior osteoporosis treatment. INTRODUCTION Understanding factors associated with reaching the contemplative stage of readiness to initiate osteoporosis treatment may inform the design of behavioral interventions to improve osteoporosis treatment uptake in women at high risk for fracture. METHODS We measured readiness to initiate osteoporosis treatment using a modified form of the Weinstein Precaution Adoption Process Model (PAPM) among 2684 women at high risk of fracture from the Activating Patients at Risk for OsteoPOroSis (APROPOS) clinical trial. Pre-contemplative participants were those who self-classified in the unaware and unengaged stages of PAPM (stages 1 and 2). Contemplative participants were those in the undecided, decided not to act, or decided to act stages of PAPM (stages 3, 4, and 5). Using multivariable logistic regression, we evaluated participant characteristics associated with levels of readiness to initiate osteoporosis treatment. RESULTS Overall, 24% (N = 412) self-classified in the contemplative stage of readiness to initiate osteoporosis treatment. After adjusting for age, race, education, health literacy, and major osteoporotic fracture in the past 12 months, contemplative women were more likely to report previously being told they had osteoporosis or osteopenia (adjusted odds ratio [aOR] (95% CI) 11.8 (7.8-17.9) and 3.8 (2.5-5.6), respectively), acknowledge concern about osteoporosis (aOR 3.5 (2.5-4.9)), and disclose prior osteoporosis treatment (aOR 4.5 (3.3-6.3)) than women who self-classified as pre-contemplative. CONCLUSIONS For women at high risk for future fractures, ensuring women's recognition of their diagnosis of osteoporosis/osteopenia and addressing their concerns about osteoporosis are critical components to consider when attempting to influence stage of behavior transitions in osteoporosis treatment.
Collapse
Affiliation(s)
- G Adami
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
- Rheumatology Unit, University of Verona, Verona, Italy
| | - K G Saag
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - A S Mudano
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - E J Rahn
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - N C Wright
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - R C Outman
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - S L Greenspan
- University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - A Z LaCroix
- Group Health Cooperative, Seattle, WA, 98112, USA
- University of California San Diego, La Jolla, CA, 92093, USA
| | - J W Nieves
- Helen Hayes Hospital, West Haverstraw, NY, 10993, USA
| | - S L Silverman
- Cedars-Sinai Medical Center, Los Angeles, CA, 30211, USA
| | - E S Siris
- Columbia University Medical Center, New York, NY, 10032, USA
| | - N B Watts
- Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, 45236, USA
| | - M J Miller
- Texas A&M University, College Station, TX, 77843, USA
- Kaiser Permanente, Rockville, MD, 20852, USA
| | - S Ladores
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - J R Curtis
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA
| | - M I Danila
- University of Alabama at Birmingham, Birmingham, AL, 35233, USA.
| |
Collapse
|
3
|
Parada H, Bellettiere J, Evenson KR, LaMonte MJ, LaCroix AZ. Accelerometer-measured Physical Activity and Breast Cancer Incidence in the WHI OPACH Study. Cancer Epidemiol Biomarkers Prev 2020. [DOI: 10.1158/1055-9965.epi-20-0055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
To examine the associations between accelerometer-measured physical activity (PA) and breast cancer incidence among a cohort of postmenopausal women. Methods: This longitudinal study included 6,382 women (mean age 79 ± 6 years; 49.4% non-Hispanic white, 33.7% non-Hispanic Black, 16.9% Hispanic) without a history of breast cancer who participated in the Women's Health Initiative (WHI) Objective Physical Activity and Cardiovascular Health (OPACH) Study. During 2012–2013, participants wore an ActiGraph GT3X+ accelerometer at the hip for up to 7 days. Accelerometer intensity counts were specially calibrated to PA in older women. The resulting data were used to compute minutes per day spent in total PA, light intensity PA (e.g., usual walking), and moderate-to-vigorous PA (MVPA; e.g., brisk walking). Physician-adjudicated first diagnosis of in situ (n = 18) or invasive (n = 103) breast cancer was ascertained over a median follow-up of 5.6 years. We used multivariable Cox regression to estimate covariate-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for tertiles and one-standard deviation (SD) unit increments of PA exposures in association with breast cancer incidence. We examined effect measure modification by age, race/ethnicity, body mass index (BMI), and smoking history. Results: The highest (vs. lowest) tertile of total PA was associated with a breast cancer incidence HR of 0.67 (95% CI = 0.43–1.05) and this association was more pronounced for MVPA (HR = 0.61, 95% CI = 0.38–1.00) than for light PA (HR = 0.81, 95% CI = 0.53–1.26). In BMI-stratified analyses, HRs for total (PInteraction = 0.04) and light PA (PInteraction = 0.01), but not MVPA (PInteraction = 0.79), were stronger among women with BMI ≥ 30 kg/m2 (n cancer events = 48; total PA HRper one-SD = 0.69, 95% CI = 0.50–0.96; light PA HR = 0.69, 95% CI = 0.50–0.95) than among women with BMI < 30 kg/m2 (n cancer events = 73; total PA HRper one-SD = 1.07, 95% CI = 0.84–1.38; light PA HR = 1.13, 95% CI = 0.89–1.44). Age, race/ethnicity, and cigarette smoking history did not strongly modify these associations (PInteraction's ≥ 0.16). Conclusions: Engaging in high levels of PA may play a beneficial role in the prevention of breast cancer in older women, and in particular among postmenopausal women with BMI ≥ 30 kg/m2.
Collapse
|
4
|
Cavanaugh AM, Rauh MJ, Thompson CA, Alcaraz J, Mihalko WM, Bird CE, Eaton CB, Rosal MC, Li W, Shadyab AH, Gilmer T, LaCroix AZ. Racial and ethnic disparities in utilization of total knee arthroplasty among older women. Osteoarthritis Cartilage 2019; 27:1746-1754. [PMID: 31404657 PMCID: PMC6875623 DOI: 10.1016/j.joca.2019.07.015] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Revised: 07/14/2019] [Accepted: 07/31/2019] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To evaluate racial and ethnic disparities in utilization of total knee arthroplasty (TKA) in relation to demographic, health, and socioeconomic status variables. DESIGN Prospective study of 102,767 Women's Health Initiative postmenopausal women initially aged 50-79, examining utilization rates of primary TKA between non-Hispanic Black/African American, non-Hispanic White, and Hispanic/Latina women (hereafter referred to as Black, White, and Hispanic). A total of 8,942 Black, 3,405 Hispanic, and 90,420 White women with linked Medicare claims data were followed until time of TKA, death, or transition from fee-for-service coverage. Absolute disparities were determined using utilization rates by racial/ethnic group and relative disparities quantified using multivariable hazards models in adjusting for age, arthritis, joint pain, mobility disability, body mass index, number of comorbidities, income, education, neighborhood socioeconomic status (SES), and geographic region. RESULTS TKA utilization was higher among White women (10.7/1,000 person-years) compared to Black (8.5/1,000 person-years) and Hispanic women (7.6/1,000 person-years). Among women with health indicators for TKA including diagnosis of arthritis, moderate to severe joint pain, and mobility disability, Black and Hispanic women were significantly less likely to undergo TKA after adjusting for age [Black: HR (95% confidence interval) = 0.70 (0.63-0.79); Hispanic: HR = 0.58 (0.44-0.77)]. Adjustment for SES modestly attenuated the measured disparity, but significant differences remained [Black: HR = 0.75 (0.67-0.89); Hispanic: HR = 0.65 (0.47-0.89)]. CONCLUSIONS Compared to White women, Black and Hispanic women were significantly less likely to undergo TKA after considering need and appropriateness for TKA and SES. Further investigation into personal-level and provider-level factors that may explain these disparities is warranted.
Collapse
Affiliation(s)
- A M Cavanaugh
- San Diego State University/University of California San Diego, Joint Doctoral Program in Public Health, USA.
| | - M J Rauh
- Doctor of Physical Therapy Program, San Diego State University, San Diego, CA, USA; Graduate School of Public Health, San Diego State University, San Diego, CA, USA.
| | - C A Thompson
- Graduate School of Public Health, San Diego State University, San Diego, CA, USA.
| | - J Alcaraz
- Graduate School of Public Health, San Diego State University, San Diego, CA, USA.
| | - W M Mihalko
- Campbell Clinic Department of Orthopaedic Surgery and Biomedical Engineering, University of Tennessee, Memphis, TN, USA.
| | - C E Bird
- Health Care Division, RAND, Santa Monica, CA, USA.
| | - C B Eaton
- Department of Family Medicine at Warren Alpert Medical School and Department of Epidemiology at School of Public Health at Brown University, Providence, RI, USA.
| | - M C Rosal
- Department of Population and Quantitative Sciences, University of Massachusetts Medical School, USA.
| | - W Li
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
| | - A H Shadyab
- Department of Family Medicine and Public Health, University of California, San Diego, CA, USA.
| | - T Gilmer
- Department of Family Medicine and Public Health, University of California, San Diego, CA, USA.
| | - A Z LaCroix
- Department of Family Medicine and Public Health, University of California, San Diego, CA, USA.
| |
Collapse
|
5
|
Trabert B, Bauer DC, Brinton LA, Buist DS, Cauley JA, Dallal CM, Gierach GL, Falk RT, Hue TF, Lacey JV, LaCroix AZ, Tice JA, Xu X. Abstract P1-08-04: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Trabert B, Bauer DC, Brinton LA, Buist DS, Cauley JA, Dallal CM, Gierach GL, Falk RT, Hue TF, Lacey, Jr. JV, LaCroix AZ, Tice JA, Xu X. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-04.
Collapse
Affiliation(s)
- B Trabert
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - DC Bauer
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - LA Brinton
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - DS Buist
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - JA Cauley
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - CM Dallal
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - GL Gierach
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - RT Falk
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - TF Hue
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - JV Lacey
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - AZ LaCroix
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - JA Tice
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| | - X Xu
- National Cancer Institute, Bethesda, MD; University of California San Francisco, San Francisco, CA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; University of Pittsburgh, Pittsburgh, PA; University of Maryland, College Park, MD; City of Hope, Duarte, CA; University of Washington, Seattle, WA; Leidos Biomedical Research, Inc., Frederick, MD
| |
Collapse
|
6
|
Acerbi I, Shieh Y, Madlensky L, Tice J, Ziv E, Eklund M, Blanco A, DeRosa D, Tong B, Goodman D, Nassereddine L, Anderson N, Harvey H, Layton T, Park HL, Petruse A, Stewart S, Wernisch J, Risty L, Koenig B, Sarrafan S, Firouzian R, Kaplan C, Hiatt R, Parker BA, Wenger N, Lee V, Heditsian D, Brain S, Stover Fiscalini A, Borowsky AD, Anton-Culver H, Naeim A, Kaster A, Talley M, van 't Veer LJ, LaCroix A, Esserman LJ. Abstract OT2-08-01: Personalized breast cancer screening in a population based study: Women Informed to Screen Depending On Measures of risk (WISDOM). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: WISDOM is a 100,000 healthy women preference-tolerant, pragmatic study comparing annual to personalized risk-based breast screening. The novelty of WISDOM personalized screening is the integration of previously validated genetic and clinical risk factors (age, family history, breast biopsy results, ethnicity, mammographic density) into a single risk assessment model that directs the starting age, timing, and frequency of screening. The goal of WISDOM is to determine if personalized screening, compared to annual screening, is as safe, less morbid, enables prevention, and is preferred by women. The study is registered on ClinicalTrials.gov, NCT02620852.
Methods: Women aged 40-74 years with no history of breast cancer or DCIS, and no previous double mastectomy can join the study online at wisdomstudy.org. Participants can elect randomization or self-select a study arm, and provide electronic consent and Release for Medical Information using DocuSign. For all participants, 5-year risk of developing breast cancer is calculated according to the Breast Cancer Screening Consortium (BCSC) model. Participants in the personalized arm undergo panel-based mutation testing, and their 5-year risk is calculated using the BCSC score combined with a Polygenic Risk Score (BCSC-PRS) that includes 75 single nucleotide polymorphisms (SNPs, increase to 229) known to increase breast cancer risk. SNPs and mutations (BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, ATM, PALB2, and CHEK2) are assessed by saliva-based testing through Color Genomics. 5-year risk level thresholds are used to stratify for low-, moderate- and high risk. Risk stratification determines age to start, stop, and frequency of screening.
Enrollment: As of July 2018, the WISDOM study is open to all eligible women in California, North Dakota, South Dakota, Minnesota and Iowa. To date, 23,329 eligible women have registered and 14,393 women have consented to participate in the trial. We analyzed 3,255 participants who have completed risk assessment in the personalized arm. The median age was 56 years. 82% were Caucasian, 1% African-American, and 6% Asian. 9% self-reported as Hispanic. We are partnering with health insurers and self-insured companies using coverage with evidence progression. To strengthen generalizability, we are expanding to other states. WISDOM enrollment will continue past 2019.
Feasibility: To evaluate the addition of PRS, we used paired statistical tests (McNemar) to compare the distributions of BCSC, and BCSC-PRS risk estimates around low-risk (<1.3%), and very-high risk (>6%) thresholds, the latter corresponding to 5-year risk of a BRCA mutation carrier. The median 5-year risk was 1.5% (IQR 1.0-2.1%) using the BCSC model, and 1.4% (IQR 0.8-2.5%) using the BCSC-PRS model. The BCSC-PRS model classified more women into the low (<1%) and very high (≥6%) risk categories compared to the BCSC model (p < 0.001).
Conclusions: Our findings demonstrate that incorporating genetic variants into a validated clinical model is feasible and impacts risk classification compared to a model without genetic risk factors. Results at 5 years will reveal if this classification improves healthcare value by reducing screen volumes and costs without jeopardizing outcomes.
Citation Format: Acerbi I, Shieh Y, Madlensky L, Tice J, Ziv E, Eklund M, Blanco A, DeRosa D, Tong B, Goodman D, Nassereddine L, Anderson N, Harvey H, Layton T, Park HL, Petruse A, Stewart S, Wernisch J, Risty L, Koenig B, Sarrafan S, Firouzian R, Kaplan C, Hiatt R, Parker BA, Wenger N, Lee V, Heditsian D, Brain S, Stover Fiscalini A, Borowsky AD, Anton-Culver H, Naeim A, Kaster A, Talley M, van 't Veer LJ, LaCroix A, Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ. Personalized breast cancer screening in a population based study: Women Informed to Screen Depending On Measures of risk (WISDOM) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-08-01.
Collapse
Affiliation(s)
- I Acerbi
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - Y Shieh
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - L Madlensky
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - J Tice
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - E Ziv
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - M Eklund
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Blanco
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - D DeRosa
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - B Tong
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - D Goodman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - L Nassereddine
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - N Anderson
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - H Harvey
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - T Layton
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - HL Park
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Petruse
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - S Stewart
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - J Wernisch
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - L Risty
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - B Koenig
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - S Sarrafan
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - R Firouzian
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - C Kaplan
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - R Hiatt
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - BA Parker
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - N Wenger
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - V Lee
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - D Heditsian
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - S Brain
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Stover Fiscalini
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - AD Borowsky
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - H Anton-Culver
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Naeim
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A Kaster
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - M Talley
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - LJ van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - A LaCroix
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD; Karolinska Institutet, Stockholm, Sweden
| | | |
Collapse
|
7
|
Bellettiere J, LaCroix AZ, LaMonte MJ, Rosenberg DE, Di C. SEDENTARY BEHAVIOR AND INCIDENT DIABETES IN OLDER WOMEN. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Bellettiere
- University of California, San Diego, La Jolla, California, United States
| | - A Z LaCroix
- University of California, San Diego, La Jolla, California, USA
| | - M J LaMonte
- University at Buffalo-SUNY, Buffalo, NY, USA
| | - D E Rosenberg
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA
| | - C Di
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| |
Collapse
|
8
|
LaMonte MJ, Rillamas-Sun E, Bellettiere J, Rosenberg DE, LaCroix AZ. SEDENTARY BEHAVIOR: IMPORTANT TO HEALTH, DIFFICULT TO MEASURE. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M J LaMonte
- Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, Buffalo, New York, United States
| | - E Rillamas-Sun
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J Bellettiere
- University of California, San Diego, La Jolla, California, USA; Center for Behavioral Epidemiology and Community Health, San Diego, California, USA
| | - D E Rosenberg
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA
| | - A Z LaCroix
- University of California, San Diego, La Jolla, California, USA
| |
Collapse
|
9
|
LaCroix AZ, Bellettiere J, LaMonte MJ, Rosenberg DE. SEDENTARY BEHAVIOR AND MORTALITY IN OLDER WOMEN. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Z LaCroix
- University of California, San Diego, La Jolla, California, United States
| | - J Bellettiere
- University of California, San Diego, La Jolla, California, USA; Center for Behavioral Epidemiology and Community Health, San Diego, California, USA
| | - M J LaMonte
- University at Buffalo-SUNY, Buffalo, NY, USA
| | - D E Rosenberg
- Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA
| |
Collapse
|
10
|
LaCroix AZ. PATTERNS OF SEDENTARY BEHAVIOR AND HEALTH OUTCOMES IN AGING WOMEN: THE OPACH STUDY. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Z LaCroix
- University of California, San Diego, La Jolla, California
| |
Collapse
|
11
|
Rosenberg DE, Di C, Rillamas-Sun E, Bellettiere J, LaMonte MJ, Buchner D, Zheng Y, LaCroix AZ. PATTERNS OF SEDENTARY TIME AND FALLS INCIDENCE IN OLDER WOMEN. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.3023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- D E Rosenberg
- Kaiser Permanente Washington Health Research Institute (formerly the Group Health Research Institute), Seattle, Washington, United States
| | - C Di
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - E Rillamas-Sun
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J Bellettiere
- University of California, San Diego, La Jolla, California, USA; Center for Behavioral Epidemiology and Community Health, San Diego, California, USA
| | - M J LaMonte
- University at Buffalo-SUNY, Buffalo, NY, USA
| | - D Buchner
- University of Illinois at Urbana-Champaign, Champaign, IL, USA
| | - Y Zheng
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - A Z LaCroix
- University of California, San Diego, La Jolla, California, USA
| |
Collapse
|
12
|
Harrington LB, Blondon M, Cushman M, Kaunitz AM, Allison MA, Wang L, Sullivan S, Woods NF, LaCroix AZ, Heckbert SR, McKnight B, Rossouw J, Smith NL. Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women. J Thromb Haemost 2018; 16:886-892. [PMID: 29504242 PMCID: PMC5932241 DOI: 10.1111/jth.13993] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Indexed: 11/30/2022]
Abstract
Essentials Vasomotor symptoms have been proposed as markers of changing cardiovascular risk. In this cohort study, we evaluated these symptoms as markers of venous thrombosis (VT) risk. We found no evidence that vasomotor symptom presence or severity were associated with VT risk. Among these postmenopausal women, vasomotor symptoms are not a useful marker of VT risk. SUMMARY Background Vasomotor symptoms may be markers of changes in cardiovascular risk, but it is unknown whether these symptoms are associated with the risk of venous thrombosis (VT). Objective To evaluate the association of vasomotor symptom presence and severity with incident VT risk among postmenopausal women, independent of potential explanatory variables. Methods This cohort study included participants of the Women's Health Initiative (WHI) Hormone Therapy Trials (n = 24 508) and Observational Study (n = 87 783), analyzed separately. At baseline, women reported whether hot flashes or night sweats were present and, if so, their severity. Using Cox proportional hazards models, we estimated the VT risk associated with vasomotor symptom presence and severity, adjusted for potential explanatory variables: age, body mass index, smoking status, race/ethnicity, and time-varying current hormone therapy use. Results At baseline, WHI Hormone Therapy Trial participants were aged 64 years and WHI Observational Study participants were aged 63 years, on average. In the WHI Hormone Therapy Trials over a median of 8.2 years of follow-up, 522 women experienced a VT event. In the WHI Observational Study, over 7.9 years of follow-up, 1103 women experienced a VT event. In adjusted analyses, we found no evidence of an association between vasomotor symptom presence (hazard ratio [HR]adj 0.91, 95% confidence interval [CI] 0.75-1.1 in the WHI Hormone Therapy Trials; HRadj 1.1, 95% CI 0.99-1.3 in the WHI Observational Study) or severity (HRadj for severe versus mild 0.99, 95% CI 0.53-1.9 in the WHI Hormone Therapy Trials; HRadj 1.3, 95% CI 0.89-2.0) in the WHI Observational Study) and the risk of incident VT. Conclusions Although vasomotor symptoms have been associated with the risk of other cardiovascular events in published studies, our findings do not suggest that vasomotor symptoms constitute a marker of VT risk.
Collapse
Affiliation(s)
- L B Harrington
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - M Blondon
- Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - M Cushman
- Department of Medicine, University of Vermont, Burlington, VT, USA
| | - A M Kaunitz
- Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA
| | - M A Allison
- Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA
| | - L Wang
- Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
| | - S Sullivan
- Department of Endocrinology, Medstar Georgetown University Hospital and Medstar Washington Hospital Center, Washington, DC, USA
| | - N F Woods
- School of Nursing, University of Washington, Seattle, WA, USA
| | - A Z LaCroix
- Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA
| | - S R Heckbert
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - B McKnight
- Department of Biostatistics, University of Washington, Seattle, WA, USA
| | - J Rossouw
- National Heart Lung and Blood Institute, Bethesda, MD, USA
| | - N L Smith
- Department of Epidemiology, University of Washington, Seattle, WA, USA
- Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA
- Department of Veterans Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center, Seattle, WA, USA
| |
Collapse
|
13
|
Naeim A, Sepucha K, Wenger N, Eklund M, Annette S, Madlensky L, van't Veer L, Parker B, Yau C, Cink T, Anton-Culver H, Borowsky A, Petruse A, Sarrafan S, Stover-Fiscalini A, LaCroix A, Adduci K, Laura E. Abstract PD2-14: Participation in a personalized breast cancer screening trial does not increase anxiety at baseline. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd2-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The purpose of this study is to examine whether participation in a personalized screening trial is associated with anxiety or breast cancer worry. The Patient Centered Outcomes Research Institute recently funded WISDOM (Women Informed to Screen Depending On Measures of risk), which is a randomized trial that tests the safety and efficacy of basing starting age, stopping age, frequency and modality of breast cancer screening on individual risk (Clinical Trials Identifier NCT02620852).
Methods: In WISDOM, participants can be randomized to annual screening or personalized screening arm, or self-select an arm an observational cohort. This interim analysis examined the first 1817 participants to determine if the personalized risk arm is acceptable and to explore whether baseline anxiety was associated with study arm. For acceptability our target was to have >60% of participants agree to randomization. Participants completed questions about their Risk Perception, the PROMIS Anxiety short form 8a (total scores 8-40 with higher scores indicating more anxiety), and Breast Cancer Risk Worry (BCRW) survey (total scores 5-20) with higher scores indicating more worry) at baseline and before they were given information on their personal risk or study assignment. For the purposes of these analyses, we defined high anxiety to be the percentage of participants scoring =>22 on the PROMIS and >8 on the BCRW.
Results: The participants were recruited from three sites (UCSD, UCSF, Sanford Health). Of the 1817 initial participants, 1643 completed the baseline questionnaire. Participants has a mean age of 57 years (SD 9). 15.8% felt their chances of developing breast cancer was high, 19.5% felt their chance of developing breast cancer was greater than the average women, and 56.6% felt their lifetime risk of developing breast cancer was >25. Risk perception was not significantly different between women who opted to be randomized versus the observational arm.
The majority of participants were willing to be randomly assigned to an arm (1071/1643, 65.1%). Of those who joined the observational cohort, the majority selected personalized risk arm (474/572, 82.9%). Overall, PROMIS anxiety scores were low at baseline (14.0 MEAN (SD 4.6)) as were the Breast Cancer Risk Worry scores (5.7 MEAN (SD 1.05)). Less than 8% of participants had PROMIS scores >22 and that did not vary across the randomized or observational groups (P=0.2)). About 2% of participants had a BCRW scores >8. Women who worried with breast cancer were more likely to select to be in the observational (3.5%) than randomized (1.7%) arm of the study (P=0.02).
Conclusions: For the women approached to participate in Wisdom, personalized screening was acceptable alternative to annual mammography. Participants in general overestimated their lifetime risk of breast cancer, had very low anxiety and low breast cancer worry. Those who were worried about breast cancer opted more often for the observational arm of the study to allow them to choose between the personalized versus annual arm. Future analyses will follow participants prospectively to determine adherence to assigned or selected arm, and whether anxiety changes after receipt of their personalized risk information.
Citation Format: Naeim A, Sepucha K, Wenger N, Eklund M, Annette S, Madlensky L, van't Veer L, Parker B, Yau C, Cink T, Anton-Culver H, Borowsky A, Petruse A, Sarrafan S, Stover-Fiscalini A, LaCroix A, Adduci K, Wisdom Advocate Partners, Laura E. Participation in a personalized breast cancer screening trial does not increase anxiety at baseline [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD2-14.
Collapse
Affiliation(s)
- A Naeim
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - K Sepucha
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - N Wenger
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - M Eklund
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - S Annette
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - L Madlensky
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - L van't Veer
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - B Parker
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - C Yau
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - T Cink
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - H Anton-Culver
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - A Borowsky
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - A Petruse
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - S Sarrafan
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - A Stover-Fiscalini
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - A LaCroix
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - K Adduci
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | - E Laura
- David Geffen UCLA School of Medicine; Harvard Medical School; Karolinski Institute; University of California, San Diego; University of California, San Franscisco; Sanford Health; University of California, Irvine; University of California, Davis
| | | |
Collapse
|
14
|
Acerbi I, Abihider K, Ling J, Layton T, DeRosa D, Madlensky L, Tice J, Shieh Y, Ziv E, Sarrafan S, Firouzian R, Tong B, Blanco A, Lee V, Heditsian D, Brain S, Kaplan C, Borowsky A, Anton-Culver H, Naeim A, Cink T, Stover Fiscalini A, Parker B, van 't Veer L, LaCroix A, Esserman L. Abstract OT3-03-01: Preference-Tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study in progress. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-03-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Women Informed to Screen Depending on Measures of risk (WISDOM) trial is a pragmatic study comparing two real world approaches to clinical care for breast screening: annual screening versus personalized screening. The novelty of the personalized arm of the study is that we are combining known risk factors (age, family history, history of breast disease, ethnicity, BIRADS breast density, and genetics) into a single risk assessment model. All components of the model have been tested and established, but have never been used jointly.
The goal of the WISDOM study is to examine the effectiveness of personalized breast cancer screening and to bring objective recommendations to the current mammography screening debate.
Methods: The WISDOM trial will enroll 100,000 women with a preference-tolerant design that will determine if risk-based screening vs. annual screening, is as safe, less morbid, enables prevention, and is preferred by women. Women 40 - 74 years of age with no history of breast cancer or DCIS, and no previous double mastectomy can join the study from the WISDOM Study website (wisdomstudy.org). All participants sign up, elect randomization or self-select the study arm, provide electronic consent using DocuSign (eConsent), and sign a Medical Release Form. For all participants, 5-year risk of developing breast cancer is calculated according to the Breast Cancer Screening Consortium (BCSC) model. For participants in the personalized arm, the overall 5-year risk BCSC score is combined with a Polygenic Risk Score, based on a genetic test including mutations in 9 genes (BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, ATM, PALB2, and CHEK2) and a panel of 75 common single nucleotide polymorphisms known to increase breast cancer risk. Risk stratification will determine frequency of screening. The study is registered on ClinicalTrials.gov as NCT02620852.
Results: As of June 12th 2017, the WISDOM study is live at all UC medical centers and recruitment is open to all eligible women in California. Up to date 4,769 eligible women registered at all sites. 2,823 women have consented in the trial. 64% were randomized and 36% chose their screening arm. A pilot was conducted to test the logistics of online participation and examine the acceptance of the study design and approach. We are partnering with health insurance companies and self-insured companies to reach our recruitment goal.
Conclusions: Enrollment will be completed by end of 2018.
Acknowledgment: support by the Patient-Centered Outcomes Research Institute (PCORI), PCS-1402-10749 to L.J.E.
(*) Authors equally contributed to this work.
Citation Format: Acerbi I, Abihider K, Ling J, Layton T, DeRosa D, Madlensky L, Tice J, Shieh Y, Ziv E, Sarrafan S, Firouzian R, Tong B, Blanco A, Lee V, Heditsian D, Brain S, Kaplan C, Borowsky A, Anton-Culver H, Naeim A, Cink T, Stover Fiscalini A, Parker B, van 't Veer L, Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners, LaCroix A, Esserman L. Preference-Tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study in progress [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-03-01.
Collapse
Affiliation(s)
- I Acerbi
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - K Abihider
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - J Ling
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - T Layton
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - D DeRosa
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - L Madlensky
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - J Tice
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - Y Shieh
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - E Ziv
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - S Sarrafan
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - R Firouzian
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - B Tong
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - A Blanco
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - V Lee
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - D Heditsian
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - S Brain
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - C Kaplan
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - A Borowsky
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - H Anton-Culver
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - A Naeim
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - T Cink
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - A Stover Fiscalini
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - B Parker
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - L van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - A LaCroix
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | - L Esserman
- University of California, San Francisco, San Francisco, CA; University of California, San Diego, San Diego, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; Sanford Health, Sioux Falls, SD
| | | |
Collapse
|
15
|
Shieh Y, Ziv E, Eklund M, Sabacan L, Firouzian R, Madlensky L, Anton-Culver H, Borowsky A, LaCroix A, Naeim A, Parker B, van't Veer L, Esserman L, Tice J. Abstract P3-09-02: Risk stratification using clinical risk factors and genetic variants in a personalized screening trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-09-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Tailoring breast cancer screening according to individual risk may represent an improvement over the current practice of age-based screening. WISDOM (Women Informed to Screen Depending on Measures of Risk) is an ongoing randomized trial comparing the safety, efficacy, cost, and patient acceptability of personalized versus annual screening. Women in the personalized arm receive screening recommendations based on sequencing of 9 genes associated with hereditary breast cancer and a 5-year risk estimate from the Breast Cancer Surveillance Consortium (BCSC) risk model modified by a polygenic risk score (PRS) comprised of 75 single nucleotide polymorphisms. WISDOM represents the first-ever use of a PRS to prospectively modify risk estimates and allows comparison of risk model performance in a population-based setting. Thus, we evaluated the risk estimates generated by: 1) the Breast Cancer Risk Assessment Tool (BCRAT) based on the Gail model, 2) the BCSC model, and 3) the BCSC model modified by the PRS (BCSC-PRS).
Methods: We analyzed participants in the personalized screening arm of the WISDOM Study (NCT02620852). The trial opened in October 2016 and is enrolling participants aged 40-74 years. Participants' self-reported demographic and risk factor information were collected through an online portal. Genotyping of participants in the personalized arm was done using a custom panel from Color Genomics. 5-year risk estimates were generated using the BCRAT (2011 version), BCSC, and BCSC-PRS models. In the latter, the PRS was used as a Bayesian likelihood ratio to modify the BCSC 5-year risk estimate. We compared the distributions of BCRAT, BCSC, and BCSC-PRS risk estimates around a low-risk (<1%) and moderately high-risk (≥3%) threshold using a paired statistical test (McNemar).
Results: To date, WISDOM has enrolled 2,065 participants, of whom 1,157 are in the personalized arm and 830 have completed risk assessment. The median age was 57 years (interquartile range, IQR 49-64). 83% were Caucasian, 2% African-American, and 7% Asian. 8% self-reported as Hispanic. The median 5-year risk was 1.7% (IQR 1.1-2.3%) using the BCRAT, 1.6% (IQR 1.1-2.3%) using the BCSC model, and 1.5% (IQR 0.9-2.7%) using the BCSC-PRS model. The BCSC-PRS model classified more women into the low (<1%) and moderately high (≥3%) risk categories compared with the BCRAT (p < 0.001) and BCSC model (p < 0.001), Table.
5-year risk classification according to the BCRAT, BCSC and BCSC-PRS models <1%1-3%≥3% n (%)n (%)n (%)Gail161 (19)556 (67)113 (14)BCSC159 (19)568 (68)103 (12)BCSC-PRS275 (33)379 (46)176 (21)
Discussion: Adding a PRS to the BCSC model categorized significantly more women below the low-risk threshold and above the moderately high-risk threshold compared with the BCSC model and BCRAT. Furthermore, the BCSC and BCRAT generated similar distributions of risk estimates. Follow-up with incident breast cancer data is needed to determine whether the reclassification provided by the PRS improves risk stratification and clinical outcomes. However, our preliminary findings suggest that incorporating genetic variants into a validated clinical model is feasible and could enhance risk prediction.
Citation Format: Shieh Y, Ziv E, Eklund M, Sabacan L, Firouzian R, Madlensky L, Anton-Culver H, Borowsky A, LaCroix A, Naeim A, Parker B, van't Veer L, Esserman L, Tice J, WISDOM Study and Athena Network Investigators WS. Risk stratification using clinical risk factors and genetic variants in a personalized screening trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-09-02.
Collapse
Affiliation(s)
- Y Shieh
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - E Ziv
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - M Eklund
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - L Sabacan
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - R Firouzian
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - L Madlensky
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - H Anton-Culver
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - A Borowsky
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - A LaCroix
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - A Naeim
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - B Parker
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - L van't Veer
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - L Esserman
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | - J Tice
- University of California San Francisco, San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; University of California San Diego, San Diego, CA; University of California Irvine, Irvine, CA; University of California Davis, Sacramento, CA; University of California Los Angeles, Los Angeles, CA; WISDOM Study and Athena Network Investigators
| | | |
Collapse
|
16
|
Litwic AE, Compston JE, Wyman A, Siris ES, Gehlbach SH, Adachi JD, Chapurlat R, Díez-Pérez A, LaCroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Watts NB, Greenspan SL, March L, Gregson CL, Cooper C, Dennison EM. Self-perception of fracture risk: what can it tell us? Osteoporos Int 2017; 28:3495-3500. [PMID: 28861636 PMCID: PMC5759929 DOI: 10.1007/s00198-017-4200-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 08/16/2017] [Indexed: 11/28/2022]
Abstract
UNLABELLED In this study, we report that self-perception of fracture risk captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is associated with improved medication uptake. It suggests that adequate appreciation of fracture risk may be beneficial and lead to greater healthcare engagement and treatment. INTRODUCTION This study aimed to assess how well self-perception of fracture risk, and fracture risk as estimated by the fracture prediction tool FRAX, related to fracture incidence and uptake and persistence of anti-osteoporosis medication among women participating in the Global Longitudinal study of Osteoporosis in Women (GLOW). METHODS GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America and Australia. Aged ≥ 55 years, 60,393 women completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk (SPR). Annual follow-up included self-reported incident fractures and anti-osteoporosis medication (AOM) use. We calculated FRAX risk without bone mineral density measurement. RESULTS Of the 39,241 women with at least 1 year of follow-up data, 2132 (5.4%) sustained an incident major osteoporotic fracture over 5 years of follow-up. Within each SPR category, risk of fracture increased as the FRAX categorisation of risk increased. In GLOW, only 11% of women with a lower baseline SPR were taking AOM at baseline, compared with 46% of women with a higher SPR. AOM use tended to increase in the years after a reported fracture. However, women with a lower SPR who were fractured still reported lower AOM rates than women with or without a fracture but had a higher SPR. CONCLUSIONS These results suggest that SPR captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is also associated with improved medication uptake.
Collapse
Affiliation(s)
- A E Litwic
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
| | | | - A Wyman
- Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA
| | - E S Siris
- Department of Medicine, Columbia University Medical Center, New York, NY, USA
| | - S H Gehlbach
- Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA
| | - J D Adachi
- St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
| | - R Chapurlat
- INSERM U831, Division of Rheumatology, Hôpital E. Herriot, Université de Lyon, Lyon, France
| | - A Díez-Pérez
- Hospital del Mar-IMIM-Autonomous, University of Barcelona, Barcelona, Spain
| | - A Z LaCroix
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J W Nieves
- Helen Hayes Hospital and Columbia University, West Haverstraw, NY, USA
| | - J C Netelenbos
- Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands
| | - J Pfeilschifter
- Department of Internal Medicine III, Alfried Krupp Krankenhaus, Essen, Germany
| | - M Rossini
- Department of Rheumatology, University of Verona, Verona, Italy
| | - C Roux
- Cochin Hospital, Paris Descartes University, Paris, France
| | - K G Saag
- University of Alabama-Birmingham, Birmingham, AL, USA
| | - S Silverman
- Department of Rheumatology, Cedars-Sinai/UCLA, Los Angeles, CA, USA
| | - N B Watts
- Bone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA
| | | | - L March
- Faculty of Medicine and Department of Public Health, University of Sydney, Sydney, Australia
| | - C L Gregson
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
- Musculoskeletal Research Unit, Learning and Research Building, Southmead Hospital, University of Bristol, Bristol, UK
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
- Institute of Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - E M Dennison
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
| | | |
Collapse
|
17
|
Bai J, Di C, Xiao L, Evenson K, LaCroix A, Crainiceanu C, Buchner D. AN ACTIVITY INDEX FOR RAW ACCELEROMETRY DATA AND ITS APPLICATION IN OLDER ADULTS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.4497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J. Bai
- Department of Biostatistics, Johns Hopkins University, Baltimore, Maryland,
| | - C. Di
- Fred Hutchinson Cancer Research Center, Seattle, Washington,
| | - L. Xiao
- North Carolina State University at Raleigh, Raleigh, North Carolina,
| | - K.R. Evenson
- University of North Carolina – Chapel Hill, Chapel Hill, North Carolina,
| | - A. LaCroix
- University of California, San Diego, La Jolla, California,
| | - C. Crainiceanu
- Department of Biostatistics, Johns Hopkins University, Baltimore, Maryland,
| | - D.M. Buchner
- University of Illinois at Urbana-Champaign, Champaign, Illinois
| |
Collapse
|
18
|
LaMonte M, Rillamas-Sun E, Evenson K, Lee I, Bellettiere J, Buchner D, Di C, LaCroix A. ACCELEROMETER PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOR AND MORTALITY RISK IN OLDER WOMEN: THE OPACH STUDY. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.4315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M.J. LaMonte
- Epidemiology, University at Buffalo - SUNY, Buffalo, New York,
| | | | - K.R. Evenson
- University of North Carolina Chapel Hill, Chapel Hill, North Carolina,
| | - I. Lee
- Harvard University, Boston, Massachusetts,
| | - J. Bellettiere
- University of California San Diego, San Diego, California,
| | - D.M. Buchner
- University of Illinois Urbana-Champaign, Urbana-Champaign, Illinois
| | - C. Di
- Fred Hutchinson Cancer Institute, Seattle, Washington,
| | - A. LaCroix
- University of California San Diego, San Diego, California,
| |
Collapse
|
19
|
Stover Fiscalini A, Theiner S, Kaplan C, Sarrafan S, Sawyer S, Liang A, Rosenberg-Wohl S, Gordon D, Frick M, Borowsky A, Anton-Culver H, Naeim A, LaCroix A, Cink T, Esserman L, van 't Veer L. Abstract P5-02-03: Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The WISDOM Study (Women Informed to Screen Depending on Measures of risk) aims to examine the effectiveness of personalized breast cancer screening and to bring objective recommendations to the current mammography screening debate. The WISDOM Study is a 100,000 woman randomized trial with a preference-tolerant design that will determine if risk-based screening (RBS) vs. annual screening, is as safe, less morbid, enables prevention and is preferred by women. A pilot was conducted to test the logistics of online participation and examine the acceptance of the study design and approach.
Methods: Women were recruited from the UCSF site of the Athena Breast Health Network, a clinical care-research cohort of 110,000 women from the 5 University of California Medical Centers and Sanford Health. The pilot recruited women via email who were 40 -74 years of age with no history of breast cancer and a normal mammogram in the past year. Those interested visited the WISDOM Study website (wisdomstudy.org), signed up, elected randomization or self-selection, provided electronic consent using DocuSign (eConsent), and completed genetic testing (RBS arm). The Breast Cancer Surveillance Consortium (BCSC) model (standard risk factors, ethnicity, and breast density) in addition to genetic testing (9 genes and 75 SNPs) was used to calculate breast cancer risks that informed the start and frequency of screening for women in the RBS arm. BCSC was also used in the annual screening arm but did not inform mammography screening recommendations. The pilot used a mixed method approach (using enrollment data, Exit Survey data, individual interviews and focus groups) to assess enrollment preferences, randomization acceptance and overall study workflow.
Results: The online electronic enrollment process and patient engagement portal was successfully implemented. In total, 639 women were invited, 235 registered (34%), and 171 (27%) consented to the pilot. Of these, 74% (127) elected to be randomized, and 26% chose to self-assign (66% chose annual screening (29)). Mean age was 56 years and the ethnic breakdown of the cohort was: 79% White, 10% Asian, 7% Latino, 3% Black, 1% other. 92% of those in the risk-based arm of the study completed genetic testing and were given results; only one genetic mutation was identified and occurred in CHEK2. Within the RBS arm (78), mammography recommendations were: 61% no further mammography until the age of 50, 22% biennial, 11% annual, and 6% every 6 month alternating MRI and mammogram. Exit Survey data illuminated confusion in study arm names (risk-based vs. annual), randomization acceptance (74%), annual arm preference in the self-selection group (66%), eConsent satisfaction (90%), enrollment process ease of use (88%), and website content, navigation and appearance satisfaction (66%). The pilot concluded in May 2016 to allow for refinements prior to the full trial.
Conclusion: Our pilot demonstrates that the majority of women are willing to be randomized and participate in an online screening study to answer the important question on optimal breast cancer screening. The pilot study results will inform implementation of the 100,000 women WISDOM Study which launches in fall of 2016.
Citation Format: Stover Fiscalini A, Theiner S, Kaplan C, Sarrafan S, Sawyer S, Liang A, Rosenberg-Wohl S, Gordon D, Frick M, Borowsky A, Anton-Culver H, Naeim A, LaCroix A, Cink T, Collaboration Athena Breast Health Network and Advocate Partners, Esserman L, van 't Veer L. Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-02-03.
Collapse
Affiliation(s)
- A Stover Fiscalini
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Theiner
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - C Kaplan
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Sarrafan
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Sawyer
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A Liang
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Rosenberg-Wohl
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - D Gordon
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - M Frick
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A Borowsky
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - H Anton-Culver
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A Naeim
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A LaCroix
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - T Cink
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - L Esserman
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - L van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | | |
Collapse
|
20
|
Mitchell C, Srinivasan S, Zhan X, Wu M, Reed S, Guthrie K, LaCroix A, Fiedler T, Munch M, Liu C, Hoffman N, Blair I, Newton K, Freeman E, Joffe H, Cohen L, Fredricks D. 1: Associations between serum estrogen, vaginal microbiota and vaginal glycogen in postmenopausal women. Am J Obstet Gynecol 2016. [DOI: 10.1016/j.ajog.2016.09.028] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Narasimmaraj PR, Stover Fiscalini A, Kaplan CP, van't Veer LJ, Hallada AM, Thompson CK, Theiner S, Borowsky A, Naeim A, Anton-Culver H, LaCroix A, Esserman LJ. Abstract P3-10-01: A pilot feasibility study of the WISDOM study, a preference-tolerant randomized controlled trial evaluating a risk-based breast cancer screening strategy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-10-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: For almost 30 years, annual mammograms for women over 40 have been a cornerstone of the US strategy to reduce breast cancer mortality. Introduction of the 2009 USPSTF screening guidelines, though based on a thorough review of the scientific literature, has triggered scientific debate and a stalemate. The solution is not to prolong the controversy with repetitious reviews of past studies, but rather to test and implement a personalized model that leverages advances in breast cancer biology, risk assessment, and imaging to provide screening recommendations based upon well-characterized measures of risk. Our WISDOM (Women Informed to Screen Depending On Measures of risk) study, a preference-tolerant randomized controlled trial funded through PCORI, will evaluate whether such a risk-based screening strategy, compared to annual screening, is as safe, is less morbid, enables prevention and is preferred by women. This upcoming pilot study will test the feasibility and technical implementation of the WISDOM trial, focusing on recruitment, enrollment, and randomization processes, a coverage with evidence development approach to enable rapid adoption, and patient experience and satisfaction. Findings will directly inform implementation of the full trial, slated to begin in fall 2015 throughout the Athena Breast Health Network, a research and care collaboration across the five UC Medical Centers and Sanford Health.
Trial Design: 225 participants will be recruited from Athena patients receiving care at UCSF. Participants must be female; between age 40 and 75; have had a normal mammogram at UCSF in the past 6 months; and in the Athena research cohort. Exclusion criteria are a breast cancer or DCIS diagnosis; inability to provide consent; or inability to speak English. After education about the trial, patients will be asked if they are willing to be randomized to either the risk-based or annual screening schedule; if not, they can self-assign to their preferred schedule. The randomized and self-assigned cohorts will receive the same interventions. The risk-based screening strategy will incorporate risk assessment based on the latest Breast Cancer Surveillance Consortium model along with established and recently validated genetic risk factors, co-morbidities, and breast density, and will be used to tailor individual recommendations for starting and stopping age, frequency, and screening modality. A saliva assay will be administered to participants in the risk-based arm to screen for genetic breast cancer risk factors (BRCA1 & BRCA2 + 9 additional genes + 81 single nucleotide polymorphisms).
Statistical Methods: Descriptive statistics for the proportion of women who are willing to be randomized, choose the risk-based arm in the self-assigned cohort, and are willing to accept their assigned or chosen screening schedule, as well as the distribution of participant anxiety scores, will be analyzed. This will inform statistical design for the full trial, including the number of women who should be approached to enroll 65,000 randomized participants and the sample size needed to measure anxiety and decision regret in the randomized cohort. Results from the pilot will be available September 30, 2015.
Citation Format: Narasimmaraj PR, Stover Fiscalini A, Kaplan CP, van't Veer LJ, Hallada AM, Thompson CK, Theiner S, Borowsky A, Naeim A, Anton-Culver H, LaCroix A, Athena Breast Health Network Investigators, Esserman LJ. A pilot feasibility study of the WISDOM study, a preference-tolerant randomized controlled trial evaluating a risk-based breast cancer screening strategy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-10-01.
Collapse
Affiliation(s)
- PR Narasimmaraj
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - A Stover Fiscalini
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - CP Kaplan
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - LJ van't Veer
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - AM Hallada
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - CK Thompson
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - S Theiner
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - A Borowsky
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - A Naeim
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - H Anton-Culver
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - A LaCroix
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | - LJ Esserman
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Davis, CA; University of California, Los Angeles, Los Angeles, CA; University of California, Irvine, Irvine, CA; University of California, San Diego, San Diego, CA; Athena Breast Health Network
| | | |
Collapse
|
22
|
Carpenter JS, Woods NF, Otte JL, Guthrie KA, Hohensee C, Newton KM, Joffe H, Cohen L, Sternfeld B, Lau RJ, Reed SD, LaCroix AZ. MsFLASH participants' priorities for alleviating menopausal symptoms. Climacteric 2015; 18:859-66. [PMID: 26517583 DOI: 10.3109/13697137.2015.1083003] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To describe self-reported menopausal symptom priorities and their association with demographics and other symptoms among participants in an intervention trial for vasomotor symptoms (VMS). METHODS Cross-sectional study embedded in the MsFLASH 02 trial, a three-by-two factorial design of yoga vs. exercise vs. usual activity and omega-3-fatty acid vs. placebo. At baseline, women (n = 354) completed hot flush diaries, a card sort task to prioritize symptoms they would most like to alleviate, and standardized questionnaires. RESULTS The most common symptom priorities were: VMS (n = 322), sleep (n = 191), concentration (n = 140), and fatigue (n = 116). In multivariate models, women who chose VMS as their top priority symptom (n = 210) reported significantly greater VMS severity (p = 0.004) and never smoking (p = 0.012), and women who chose sleep as their top priority symptom (n = 100) were more educated (p ≤ 0.001) and had worse sleep quality (p < 0.001). ROC curves identified sleep scale scores that were highly predictive of ranking sleep as a top priority symptom. CONCLUSIONS Among women entering an intervention trial for VMS and with relatively low prevalence of depression and anxiety, VMS was the priority symptom for treatment. A card sort may be a valid tool for quickly assessing symptom priorities in clinical practice and research.
Collapse
Affiliation(s)
- J S Carpenter
- a Science of Nursing Care, School of Nursing, Indiana University , Indianapolis , IN
| | - N F Woods
- b Biobehavioral Nursing, University of Washington , Seattle , WA
| | - J L Otte
- a Science of Nursing Care, School of Nursing, Indiana University , Indianapolis , IN
| | - K A Guthrie
- c Fred Hutchinson Cancer Research Center , Seattle , WA
| | - C Hohensee
- c Fred Hutchinson Cancer Research Center , Seattle , WA
| | - K M Newton
- d Group Health Research Institute , Seattle , WA
| | - H Joffe
- e Harvard Medical School, Department of Psychiatry , Brigham and Women's Hospital and Dana Farber Cancer Institute , Boston , MA
| | - L Cohen
- f Center for Women's Mental Health; Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital , Boston , MA
| | - B Sternfeld
- g Division of Research , Kaiser Permanent Medical Program of Northern California , Oakland , CA
| | - R J Lau
- h Department of Obstetrics and Gynecology , School of Medicine, Indiana University , Indianapolis , IN
| | - S D Reed
- i Departments of Obstetrics/Gynecology and Epidemiology , University of Washington School of Medicine , Seattle , WA
| | - A Z LaCroix
- j Department of Preventive Medicine , University of California San Diego , San Diego , CA , USA
| |
Collapse
|
23
|
Johansson H, Kanis JA, Odén A, Leslie WD, Fujiwara S, Glüer CC, Kroger H, LaCroix AZ, Lau E, Melton LJ, Eisman JA, O'Neill TW, Goltzman D, Reid DM, McCloskey E. Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int 2014; 95:428-35. [PMID: 25187239 PMCID: PMC4361897 DOI: 10.1007/s00223-014-9911-2] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2014] [Accepted: 08/14/2014] [Indexed: 11/30/2022]
Abstract
There are occasional marked discordances in BMD T-scores at the lumbar spine (LS) and femoral neck (FN). We investigated whether such discordances could contribute independently to fracture prediction using FRAX. We studied 21,158 women, average age 63 years, from 10 prospective cohorts with baseline FRAX variables as well as FN and LS BMD. Incident fractures were collected by self-report and/or radiographic reports. Extended Poisson regression examined the relationship between differences in LS and FN T-scores (ΔLS-FN) and fracture risk, adjusted for age, time since baseline and other factors including FRAX 10-year probability for major osteoporotic fracture calculated using FN BMD. To examine the effect of an adjustment for ΔLS-FN on reclassification, women were separated into risk categories by their FRAX major fracture probability. High risk was classified using two approaches: being above the National Osteoporosis Guideline Group intervention threshold or, separately, being in the highest third of each cohort. The absolute ΔLS-FN was greater than 2 SD for 2.5% of women and between 1 and 2 SD for 21%. ΔLS-FN was associated with a significant risk of fracture adjusted for baseline FRAX (HR per SD change = 1.09; 95% CI = 1.04-1.15). In reclassification analyses, only 2.3-3.2% of the women moved to a higher or lower risk category when using FRAX with ΔLS-FN compared with FN-derived FRAX alone. Adjustment of estimated fracture risk for a large LS/FN discrepancy (>2SD) impacts to a large extent on only a relatively small number of individuals. More moderate (1-2SD) discordances in FN and LS T-scores have a small impact on FRAX probabilities. This might still improve clinical decision-making, particularly in women with probabilities close to an intervention threshold.
Collapse
Affiliation(s)
- H Johansson
- WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Gregson CL, Dennison EM, Compston JE, Adami S, Adachi JD, Anderson FA, Boonen S, Chapurlat R, Díez-Pérez A, Greenspan SL, Hooven FH, LaCroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Siris ES, Watts NB, Wyman A, Cooper C. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int 2014; 25:85-95. [PMID: 23884437 PMCID: PMC3867337 DOI: 10.1007/s00198-013-2438-y] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Accepted: 06/27/2013] [Indexed: 12/11/2022]
Abstract
UNLABELLED Accurate patient risk perception of adverse health events promotes greater autonomy over, and motivation towards, health-related lifestyles. INTRODUCTION We compared self-perceived fracture risk and 3-year incident fracture rates in postmenopausal women with a range of morbidities in the Global Longitudinal study of Osteoporosis in Women (GLOW). METHODS GLOW is an international cohort study involving 723 physician practices across ten countries (Europe, North America, Australasia); 60,393 women aged ≥55 years completed baseline questionnaires detailing medical history and self-perceived fracture risk. Annual follow-up determined self-reported incident fractures. RESULTS In total 2,945/43,832 (6.8%) sustained an incident fracture over 3 years. All morbidities were associated with increased fracture rates, particularly Parkinson's disease (hazard ratio [HR]; 95% confidence interval [CI], 3.89; 2.78-5.44), multiple sclerosis (2.70; 1.90-3.83), cerebrovascular events (2.02; 1.67-2.46), and rheumatoid arthritis (2.15; 1.53-3.04) (all p < 0.001). Most individuals perceived their fracture risk as similar to (46%) or lower than (36%) women of the same age. While increased self-perceived fracture risk was strongly associated with incident fracture rates, only 29% experiencing a fracture perceived their risk as increased. Under-appreciation of fracture risk occurred for all morbidities, including neurological disease, where women with low self-perceived fracture risk had a fracture HR 2.39 (CI 1.74-3.29) compared with women without morbidities. CONCLUSIONS Postmenopausal women with morbidities tend to under-appreciate their risk, including in the context of neurological diseases, where fracture rates were highest in this cohort. This has important implications for health education, particularly among women with Parkinson's disease, multiple sclerosis, or cerebrovascular disease.
Collapse
Affiliation(s)
- C L Gregson
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Pfeilschifter J, Cooper C, Watts NB, Flahive J, Saag KG, Adachi JD, Boonen S, Chapurlat R, Compston JE, Díez-Pérez A, LaCroix AZ, Netelenbos JC, Rossini M, Roux C, Sambrook PN, Silverman S, Siris ES. Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. Osteoporos Int 2012; 23:2179-88. [PMID: 22086311 DOI: 10.1007/s00198-011-1840-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Accepted: 11/02/2011] [Indexed: 11/28/2022]
Abstract
UNLABELLED We examined variations in proportions of hip fractures and major fractures among postmenopausal women using the Global Longitudinal Study of Osteoporosis in Women (GLOW). The proportion of major fractures that were hip fractures varied with age and region, whereas variations in the proportion of fractures that were major fractures appeared modest. INTRODUCTION In many countries, the World Health Organization fracture risk assessment tool calculates the probability of major fractures by assuming a uniform age-associated proportion of major fractures that are hip fractures in different countries. We further explored this assumption, using data from the GLOW. METHODS GLOW is an observational population-based study of 60,393 non-institutionalized women aged ≥55 years who had visited practices within the previous 2 years. Main outcome measures were self-reported prevalent fractures after the age of 45 years and incident fractures during the 2 years of follow-up. RESULTS The adjusted proportion of prevalent and incident major fractures after the age of 45 years that were hip fractures was higher in North America (16%, 17%) than in northern (13%, 12%) and southern Europe (10%, 10%), respectively. The proportion of incident major fractures that were hip fractures increased more than five-fold with age, from 6.6% among 55-59-year-olds to 34% among those aged ≥85 years. Regional and age-associated variations in the proportion of all incident fractures that were major fractures were less marked, not exceeding 16% and 28%, respectively. CONCLUSIONS The data suggest that there may be regional differences in the proportion of major fractures that are hip fractures in postmenopausal women. In contrast, the regional and age-related variations in the proportion of fractures that are major fractures appear to be modest. However, because of the limited number of fractures in our sample, further studies are necessary to confirm these findings.
Collapse
Affiliation(s)
- J Pfeilschifter
- Department of Internal Medicine III, Alfried Krupp Krankenhaus, Essen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
LaCroix AZ, Beck TJ, Cauley JA, Lewis CE, Bassford T, Jackson R, Wu G, Chen Z. Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density? Osteoporos Int 2010; 21:919-29. [PMID: 19756830 PMCID: PMC2896704 DOI: 10.1007/s00198-009-1056-1] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2009] [Accepted: 07/27/2009] [Indexed: 10/20/2022]
Abstract
SUMMARY Hip geometry measurements of outer diameter and buckling ratio at the intertrochanter and shaft of the hip dual energy X-ray absorptiometry (DXA) scan predicted incident hip fracture in postmenopausal women. These associations, independent of age, body size, clinical risk factors, and conventional areal bone mineral density, suggest hip geometry plays a role in fracture etiology and may aid in improving identification of older women at high fracture risk. INTRODUCTION This study examined whether hip geometry parameters predicted hip fracture independent of body size, clinical risk factors, and conventional femoral neck bone mineral density (aBMD) and whether summary factors could be identified to predict hip fracture. METHODS We studied 10,290 postmenopausal women from the Women's Health Initiative. Eight thousand eight hundred forty-three remained fracture free during follow-up to 11 years of follow-up, while 147 fractured their hip, and 1,300 had other clinical fractures. Hip structural analysis software measured bone cross-sectional area, outer diameter, section modulus, average cortical thickness, and buckling ratio on archived DXA scans in three hip regions: narrow neck, intertrochanter, and shaft. Hazard ratios were estimated using Cox proportional hazards models for individual parameters and for composite factors extracted from principal components analysis from all 15 parameters. RESULTS After adjustment for age, body size, clinical risk factors, and aBMD, intertrochanter and shaft outer diameter measurements remained independent predictors of hip fracture with hazard ratios for a one standard deviation increase of 1.61 (95% confidence interval (CI), 1.25-2.08) for the intertrochanter and 1.36 (95% CI, 1.06-1.76) for the shaft. Average buckling ratios also independently predicted incident hip fracture with hazard ratios of 1.43 (95% CI, 1.10-1.87) at the intertrochanter and 1.24 (95% CI, 1.00-1.55) at the shaft. Although two composite factors were extracted from principal components analysis, neither was superior to these individual measurements at predicting incident hip fracture. CONCLUSIONS Two hip geometry parameters, intertrochanter outer diameter and buckling ratio, predict incident hip fracture after accounting for clinical risk factors and aBMD.
Collapse
Affiliation(s)
- A Z LaCroix
- WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Cauley JA, LaCroix AZ, Robbins JA, Larson J, Wallace R, Wactawski-Wende J, Chen Z, Bauer DC, Cummings SR, Jackson R. Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial. Osteoporos Int 2010; 21:167-77. [PMID: 19436934 PMCID: PMC2787820 DOI: 10.1007/s00198-009-0953-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2009] [Accepted: 03/27/2009] [Indexed: 12/26/2022]
Abstract
INTRODUCTION The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels. METHODS We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years. RESULTS There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo. CONCLUSION The effect of HT on fracture reduction is independent of estradiol and SHBG levels.
Collapse
Affiliation(s)
- J A Cauley
- Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Hooven FH, Adachi JD, Adami S, Boonen S, Compston J, Cooper C, Delmas P, Diez-Perez A, Gehlbach S, Greenspan SL, LaCroix A, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris E, Watts NB, Anderson FA. The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int 2009; 20:1107-16. [PMID: 19468663 PMCID: PMC2690851 DOI: 10.1007/s00198-009-0958-2] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2008] [Accepted: 04/21/2009] [Indexed: 11/06/2022]
Abstract
SUMMARY The Global Longitudinal study of Osteoporosis in Women (GLOW) is a prospective cohort study involving 723 physicians and 60,393 women subjects >or=55 years. The data will provide insights into the management of fracture risk in older women over 5 years, patient experience with prevention and treatment, and distribution of risk among older women on an international basis. INTRODUCTION Data from cohort studies describing the distribution of osteoporosis-related fractures and risk factors are not directly comparable and do not compare regional differences in patterns of patient management and fracture outcomes. METHODS The GLOW is a prospective, multinational, observational cohort study. Practices typical of each region were identified through primary care networks organized for administrative, research, or educational purposes. Noninstitutionalized patients visiting each practice within the previous 2 years were eligible. Self-administered questionnaires were mailed, with 2:1 oversampling of women >or=65 years. Follow-up questionnaires will be sent at 12-month intervals for 5 years. RESULTS A total of 723 physicians at 17 sites in ten countries agreed to participate. Baseline surveys were mailed (October 2006 to February 2008) to 140,416 subjects. After the exclusion of 3,265 women who were ineligible or had died, 60,393 agreed to participate. CONCLUSIONS GLOW will provide contemporary information on patterns of management of fracture risk in older women over a 5-year period. The collection of data in a similar manner in ten countries will permit comparisons of patient experience with prevention and treatment and provide insights into the distribution of risk among older women on an international basis.
Collapse
Affiliation(s)
- F H Hooven
- Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA 01605, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
|
30
|
Newton K, Reed S, LaCroix A, Grothaus L, Nekhlyudov L, Ludman E. PHYSICIAN APPROACHES TO HT DISCONTINUATION. Maturitas 2009. [DOI: 10.1016/s0378-5122(09)70141-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Powles T, Neven P, Osborne C, Goss P, Allred C, Cummings S, Wolter K, Thompson J, Armstrong R, LaCroix A. S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis. Breast 2009. [DOI: 10.1016/s0960-9776(09)70020-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
LaCroix AZ, Cummings SR, Delmas P, Eastell R, Ensrud K, Reid DM, Vukicevic S, Armstrong RA, Thompson J, Thompson D, Wolter K, Allred C, Goss P, Osborne KC, Powles TJ. Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-11] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #11
The Postmenopausal Evaluation and Risk-reduction with Lasofoxifene (PEARL) Trial evaluated the effects of 5 years of a new potent SERM on the incidence of estrogen receptor positive (ER+) breast cancer (BC) (co-primary endpoints, invasive alone and invasive plus ductal carcinoma in situ [DCIS] together). 8556 women ages 5980 with femoral neck or spine T-score ≤ –2.5 and > –4.5 were enrolled in 32 countries. Women were randomly assigned to receive 0.25 mg/d or 0.5 mg/d of lasofoxifene (LASO), or placebo (PBO). BC events were ascertained through annual clinical breast exam and mammographic screening and adjudicated by physician oncologists and a BC pathologist blinded to treatment assignment. 77% of women completed 5 years of follow-up and 62–64% remained on study medication until planned trial closure. ITT analyses were conducted using Cox Proportional Hazards models. The protocol-defined primary analysis for all ER+ BCs compared each of the LASO groups to PBO. In the PBO group, 21 women developed invasive or non-invasive ER+ BC (17.3/10,000 person-years (P-Y)) compared to 10 in the LASO 0.25 mg/d group (9.0/10,000 P-Y; HR=0.52, 95%CI 0.25–1.08) and 5 in the 0.5 mg/d LASO group (3.3/10,000 P-Y; HR=0.19, 95% CI 0.07–0.56). For all invasive BCs (ER+ve and ve), 20 women in the PBO group were affected (16.4/10,000) compared to 16 in the LASO 0.25 mg/d group (13.2/10,000 P-Y; HR=0.79, 95%CI 0.41–1.52) and 3 in the 0.5 mg/d LASO group (2.5/10,000 P-Y; HR=0.15, 95% CI 0.04–0.50). For total BC, 24 women in the PBO group were affected (19.8/10,000 P-Y) compared to 20 in the LASO 0.25 mg/d group (16.4/10,000 P-Y; HR=0.82, 95%CI 0.45–1.49) and 5 in the 0.5 mg/d LASO group (4.1/10,000 P-Y; HR=0.21, 95% CI 0.08–0.55). Too few cases of DCIS occurred to determine effects of LASO on noninvasive breast tumors. No significant differences among treatment groups were observed for breast density. LASO also reduced the incidence of vertebral (primary at 3 years) and nonvertebral clinical fractures (co-primary at 5-years). LASO increased risk of venous thromboembolic events, but not stroke, endometrial cancer or endometrial hyperplasia and decreased risk of major coronary events at 0.5 mg/d. Endometrial hypertrophy, uterine polyps, and fibroids were more common with LASO while hypertension and hyperlipidemia was less frequent compared to PBO. We conclude that LASO reduces the incidence of ER+ BC and appears to have a favorable benefit-risk profile for prevention of clinical fractures in postmenopausal women with osteoporosis.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 11.
Collapse
Affiliation(s)
- AZ LaCroix
- 1 Fred Hutchinson Cancer Research Center, Seattle, WA
| | - SR Cummings
- 2 CPMC Research Institute, San Francisco, CA
| | - P Delmas
- 3 INSERM Research Unit 831, U. of Lyon, Lyon, France
| | | | - K Ensrud
- 5 U. of Minnesota, Minneapolis, MN
| | - DM Reid
- 6 U. of Aberdeen Medical School, Aberdeen, UK
| | | | | | | | | | | | - C Allred
- 9 Washington U. School of Medicine, St. Louis, MO
| | - P Goss
- 10 Harvard Medical School, Boston, MA
| | - KC Osborne
- 11 Baylor College of Medicine, Houston, TX
| | - TJ Powles
- 12 Parkside Oncology Centre, London, UK
| |
Collapse
|
33
|
Ott SM, LaCroix AZ, Scholes D, Ichikawa LE, Wu K. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 2008; 19:1315-22. [PMID: 18425402 DOI: 10.1007/s00198-008-0612-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2007] [Accepted: 12/12/2007] [Indexed: 10/22/2022]
Abstract
UNLABELLED In this clinical trial of 12.5 or 25 mg/day of hydrochlorothiazide, the urine calcium showed significant decreases from placebo in men at one year, but the effects had waned by 3 years. Serum bicarbonate was consistently greater in the thiazide than in the placebo groups throughout the three years. These effects could be beneficial to the skeleton. INTRODUCTION Previous studies have shown increased bone density and reduced risk of fracture in patients taking thiazide diuretics. The long-term effects of low-dose thiazides on mineral metabolism have not been reported in normal subjects. METHODS We conducted a randomized, double-blinded trial in normals aged 60-79 years, using hydrochlorothiazide 12.5 or 25 mg/d or placebo for three years. Subjects were encouraged to maintain calcium intake of 1,000 to 1,500 mg/day. Measurements of serum and urine calcium metabolism were done at baseline, six months, and yearly. Data were analyzed in 88 men and 177 women who had taken study medication. Adjusted change in the measurements from baseline to one and three years were compared among groups. RESULTS The calcium intake increased in all groups. Urine calcium per day was significantly lower in thiazide than placebo groups in men at one year but not at three years; in women the changes were not significantly different. Serum bicarbonate was higher in thiazide compared to placebo groups at one and three years. No changes were seen in serum calcium, phosphate, parathyroid hormone, sodium or magnesium. CONCLUSIONS The results suggest that both increased calcium availability from a hypocalciuric effect and reduction in acid-induced bone buffering could be mechanisms for the beneficial skeletal effects.
Collapse
Affiliation(s)
- S M Ott
- University of Washington, 1959 NE Pacific Street, P. O. Box 356426, Seattle, WA 98195-6426, USA.
| | | | | | | | | |
Collapse
|
34
|
Wallace JI, Buchner DM, Grothaus L, Leveille S, Tyll L, LaCroix AZ, Wagner EH. Implementation and effectiveness of a community-based health promotion program for older adults. J Gerontol A Biol Sci Med Sci 2008; 53:M301-6. [PMID: 18314570 DOI: 10.1093/gerona/53a.4.m301] [Citation(s) in RCA: 101] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Because preventing functional decline in older adults is a national priority and senior centers have been identified as potentially important venues for health-promotion activities, a trial of a multicomponent disability prevention program was conducted at a senior center. METHODS One hundred older adults were recruited for a 6-month randomized clinical trial. All members of the experimental group received an exercise intervention, nutrition counseling, and a home safety assessment. Smoking and alcohol interventions were delivered to at-risk subjects. Outcome variables included the Medical Outcomes Study Short Form (SF-36) health survey, the CES-Depression scale, bed days, and restricted-activity days. RESULTS A single study announcement resulted in a response sufficient to recruit 100 subjects. The exercise program was well received: 85% of intervention subjects completed the 6-month program and adherence was excellent, with over 90% attendance at exercise classes. After 6 months the intervention group had significantly better scores on 7 of 8 SF-36 subscales and fewer depressive symptoms than controls. CONCLUSIONS Senior centers may be excellent sites for community-based health promotion interventions: participation and adherence rates may be acceptable, interventions can be designed that are feasible in this setting, and these interventions appear to affect health status positively. The study program improved physical and psychosocial functioning and is a promising model for preventing functional decline through activities based at senior centers.
Collapse
Affiliation(s)
- J I Wallace
- Department of Medicine, University of Washington, Seattle, USA.
| | | | | | | | | | | | | |
Collapse
|
35
|
Wetmore CM, Ichikawa L, LaCroix AZ, Ott SM, Scholes D. Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use. Osteoporos Int 2008; 19:519-27. [PMID: 18004611 DOI: 10.1007/s00198-007-0473-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2007] [Accepted: 08/24/2007] [Indexed: 10/22/2022]
Abstract
UNLABELLED This study assessed associations between habitual caffeine intake and bone mass among young women. Analyses of the entire study population revealed no significant associations, while analyses restricted to women using depot medroxyprogesterone acetate (DMPA) showed modest inverse associations between caffeine intake and bone mineral content (BMC). INTRODUCTION Some previous investigations among postmenopausal women suggest an inverse relationship between caffeine intake and bone mass, yet studies of this association among young women are few. METHODS The association between habitual caffeine intake and bone mass was evaluated prospectively in a population-based cohort of 625 females, aged 14 to 40 years, adjusting for relevant biological and lifestyle factors. Caffeinated beverage intake was self-reported, and bone mineral content (BMC) and bone mineral density (BMD) were measured at baseline and every 6 months throughout a 24-month follow-up period using dual-energy x-ray absorptiometry. RESULTS Cross-sectional analyses revealed no significant differences in mean BMC or BMD at baseline. Mean percentage and absolute changes in BMC and BMD were not associated with caffeine use. Repeated measures analyses similarly showed no significant association between caffeine intake at baseline and mean BMC or BMD measured during follow-up. However, among women using depot medroxyprogesterone acetate (DMPA), modest inverse associations between caffeine and BMC (but not BMD) were detected. CONCLUSIONS Our data suggest that heavy habitual consumption of caffeinated beverages does not adversely impact bone mass among young women in general. Greater caffeine intake may be associated with lower BMC among DMPA users.
Collapse
Affiliation(s)
- C M Wetmore
- Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
| | | | | | | | | |
Collapse
|
36
|
Newton KM, LaCroix AZ, Levy L, Li SS, Qu P, Potter JD, Lampe JW. Soy protein and bone mineral density in older men and women: A randomized trial. Maturitas 2006; 55:270-7. [PMID: 16730418 DOI: 10.1016/j.maturitas.2006.04.011] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2005] [Revised: 04/12/2006] [Accepted: 04/15/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE Test the hypothesis that soy isoflavone supplementation preserves bone mineral density (BMD) in men and women. METHODS We conducted a controlled, parallel-arm, double-blinded trial with 145 participants, 50-80 years, with random assignment to soy beverage daily for 12 months. Active treatment (+ISO) received soy protein containing 83 mg isoflavones (45.6 mg genistein, 31.7 mg daidzein), aglycone units; the comparison group (-ISO) received soy protein containing 3mg isoflavones. We measured BMD using dual-energy X-ray absorptiometry at the total hip and posterior-anterior spine (L1-L4) at baseline in 22 women and 123 men, and at 12 months in 13 women and 98 men. We used linear mixed models to test for an isoflavone effect on percentage BMD change from baseline in spine and hip. RESULTS Among all participants, mean percent change in spine BMD (+/-S.E.) was 0.16+/-0.44 in -ISO (P=0.10) at 12 months. Treatment effects on spine BMD were significantly greater in women than men (P=0.01). At 12 months, in women, mean percent change was 0.58+/-0.70 in +ISO and -1.84+/-0.86 in -ISO (P=0.05); among men it was 1.32+/-0.53 in +ISO and 0.31+/-0.48 in -ISO (P=0.16). By comparison, percent change in hip BMD was similar in the treatment groups, and was not different between men and women. Mean percent change in hip BMD from baseline to 12 months was 0.54+/-0.38 in +ISO and -0.13+/-0.36 in -ISO (P=0.20) among all participants. CONCLUSIONS Soy protein containing isoflavones showed a modest benefit in preserving spine, but not hip BMD in older women.
Collapse
Affiliation(s)
- K M Newton
- Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA.
| | | | | | | | | | | | | |
Collapse
|
37
|
Wetmore CM, Scholes D, LaCroix AZ, Ott SM, Ichikawa L. Longitudinal Analysis of the Association Between Habitual Caffeine Intake and Bone Mineral Density Among Women Aged 14 to 40. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s146-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Chen Z, Pettinger MB, Ritenbaugh C, LaCroix AZ, Robbins J, Caan BJ, Barad DH, Hakim IA. Habitual tea consumption and risk of osteoporosis: a prospective study in the women's health initiative observational cohort. Am J Epidemiol 2003; 158:772-81. [PMID: 14561667 DOI: 10.1093/aje/kwg214] [Citation(s) in RCA: 69] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The purpose of this study was to prospectively investigate associations of habitual drinking of regular tea with bone mineral density and fracture risk. Study participants were a multiethnic postmenopausal cohort (n = 91,465) from the nationwide Women's Health Initiative Observational Study. These women were recruited in the United States and aged 50-79 years at the time of enrollment (1994-1998). The average follow-up time was 4.1 years. Habitual consumption of regular tea was assessed with a structured questionnaire at baseline. Clinical fractures during the follow-up were reported in questionnaires, and hip fractures were further confirmed by reviewing medical records. Bone mineral density measurements were conducted among a subgroup of women (n = 4,979) at three Women's Health Initiative bone mineral density centers using dual-energy x-ray absorptiometry. Multivariate analyses suggested a positive trend of increased total body bone mineral density with tea drinking (p < 0.05). However, results from the Cox proportional hazard models did not show any significant association between tea drinking and the risk of fractures at the hip and forearm/wrist. In conclusion, the results from this study indicate that the effect of habitual tea drinking on bone density is small and does not significantly alter the risk of fractures among the US postmenopausal population.
Collapse
Affiliation(s)
- Z Chen
- Arizona College of Public Health, University of Arizona, Tucson, AZ 85716, USA.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Rice MM, LaCroix AZ, Lampe JW, van Belle G, Kestin M, Sumitani M, Graves AB, Larson EB. Dietary soy isoflavone intake in older Japanese American women. Public Health Nutr 2001; 4:943-52. [PMID: 11784407 DOI: 10.1079/phn2001150] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE In a sample of older Japanese American women, we aimed to: (1) describe the most commonly consumed soy foods, (2) estimate dietary soy isoflavone intake, (3) describe characteristics associated with dietary soy isoflavone intake, and (4) compare our estimates with previously published estimates in other Japanese samples. DESIGN A 14-item soy food-frequency questionnaire was administered to older Japanese American women and responses were converted to quantitative estimates of soy isoflavones (genistein plus daidzein). Multiple regression was used to examine characteristics associated with dietary soy isoflavone intake, including self-reported lifestyle and cultural factors and dietary intake of various foods ascertained from a semi-quantitative food-frequency questionnaire. To compare our estimates with other samples, a review of the literature was conducted. SETTING/SUBJECTS Data are from 274 women aged 65+ years, recruited from a longitudinal cohort study of Japanese Americans in King County, Washington State. RESULTS The soy foods most commonly consumed were tofu (soybean curd), miso (fermented soybean paste) and aburaage (fried thin soybean curd). The mean intake of dietary soy isoflavones was 10.2 (standard deviation (SD), 12.4) mg day(-1), approximately a quarter to a half that of previously published estimates in Japanese samples. Dietary soy isoflavone intake was positively associated with speaking Japanese, the consumption of traditional Japanese dishes (kamaboko, manju and mochi), low-fat/non-fat milk and yellow/red vegetables, vitamin E supplement use, and walking several blocks each day. Dietary soy isoflavone intake was negatively associated with the consumption of butter. CONCLUSIONS The estimated dietary soy isoflavone intake in Japanese American women living in King County, Washington State was about a quarter to a half that of women living in Japan. Dietary soy isoflavone intake was associated with speaking Japanese and healthy lifestyle and dietary habits.
Collapse
Affiliation(s)
- M M Rice
- Department of Epidemiology, University of Washington, Seattle, WA 98195, USA.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
OBJECTIVE Effectively communicating information about the complex decisions that face women at midlife, including whether to use hormone replacement therapy (HRT), is an ongoing challenge. Although numerous decision-making tools exist, few have been evaluated. The objective of this study was to examine women's use of a workbook designed to promote informed HRT decision-making. DESIGN We developed a workbook to prepare women to discuss HRT, osteoporosis, heart disease, and breast cancer with their providers. To evaluate the workbook, women aged 45-65 years were randomly assigned to one of three groups: (1) workbook plus baseline and 6-month surveys, (2) workbook and 6-month survey, or (3) no workbook with both surveys. Results are based on the responses of 580 women in groups 1 and 2 (response rate, 84.2%). RESULTS At 6 months, 79% of women recalled receiving the workbook, of whom 51% read all or most of it, 35% skimmed or read part of it, and 14% did not read it. The percentages of women completing self-assessments were 55% osteoporosis; 56% heart disease; 58% breast cancer; 57% advantages and disadvantages of HRT; and 52% personal preferences about HRT. As a result of the workbook, 10% made an appointment with their providers, and 12% had a discussion about HRT with their providers. Use of the workbook was not associated with menopause symptoms, attitudes about or use of HRT, hysterectomy, or provider discussions about menopause and HRT. CONCLUSION This simple approach of using a mailed workbook holds promise as a successful mechanism to prepare women to discuss HRT and other related health issues with their providers.
Collapse
Affiliation(s)
- K M Newton
- Center for Health Studies, Group Health Cooperative, Seattle, Washington 98101, USA.
| | | | | | | | | |
Collapse
|
41
|
Abstract
OBJECTIVES The purpose of this study was to compare hormone replacement therapy (HRT) prescribing frequency to provider characteristics, attitudes and beliefs about menopause and HRT. METHODS There was a mailed survey of providers at a large staff-model HMO in Washington state. Participants included 250 family practice physicians, 22 gynecologists, and 13 women's health care specialists and nurse midwives (83% response rate). The primary outcome, "HRT prescribing frequency" (derived from automated pharmacy and visit data) was defined as: the total number of estrogen prescriptions written by the provider and filled by women aged 50-80 years during the 12 months prior to the survey, divided by the number of visits made to the provider by women aged 50-80 years during that same 12-month period. Covariates included provider characteristics and beliefs about menopause and HRT. Logistic regression was used to distinguish providers in the upper 40% versus the lower 60% of HRT prescribing frequency. RESULTS Controlling for age and practice type, HRT prescribing frequency was lower among men than women providers (odds ratio [OR] 0.38, 95% confidence interval [CI] 0.21-0.65), higher among providers who agreed (vs. disagreed or neutral) that a convincing scientific case has been made that HRT prevents heart disease (OR 2.66, 95% CI 1.53-4.61), and higher among those in the upper tertile vs. lower tertiles of an HRT encouragement scale (OR 2.50, 95% CI 1.29-4.85). CONCLUSIONS Female providers and providers with positive attitudes toward HRT are the most likely to prescribe it.
Collapse
Affiliation(s)
- K M Newton
- Center for Health Studies, Group Health Cooperative, 1730 Minor Ave. Suite 1600, Seattle, WA 98101, USA.
| | | | | | | | | |
Collapse
|
42
|
Heckbert SR, Kaplan RC, Weiss NS, Psaty BM, Lin D, Furberg CD, Starr JR, Anderson GD, LaCroix AZ. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001; 161:1709-13. [PMID: 11485503 DOI: 10.1001/archinte.161.14.1709] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND The finding from the Heart and Estrogen/Progestin Replacement Study (HERS) of increased coronary risk restricted to the first year after starting postmenopausal hormone therapy raises new questions about the role of hormone therapy in women with coronary heart disease. We assessed the risk of recurrent myocardial infarction or coronary heart disease death associated with the use and recent initiation of hormone therapy in women who survived a first myocardial infarction. METHODS The setting for this population-based inception cohort study was Group Health Cooperative, a health maintenance organization. We studied 981 postmenopausal women who survived to hospital discharge after their first myocardial infarction between July 1, 1986, and December 31, 1996. We obtained information on hormone use from the Group Health Cooperative computerized pharmacy database and identified recurrent coronary events by medical record review. RESULTS During median follow-up of 3.5 years, there were 186 recurrent coronary events. There was no difference in the risk of recurrent coronary events between current users of hormone therapy and other women (adjusted relative hazard [RH], 0.96; 95% confidence interval [CI], 0.62-1.50). Relative to the risk in women not currently using hormones, there was a suggestion of increased risk during the first 60 days after starting hormone therapy (RH, 2.16; 95% CI, 0.94-4.95) and reduced risk with current hormone use for longer than 1 year (RH, 0.76; 95% CI, 0.42-1.36). CONCLUSION These results are consistent with the findings from the HERS, suggesting a transitory increase in coronary risk after starting hormone therapy in women with established coronary heart disease and a decreased risk thereafter.
Collapse
Affiliation(s)
- S R Heckbert
- Cardiovascular Health Research Unit, University of Washington, 1730 Minor Ave, Suite 1360, Seattle, WA 98101-1448, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Buist DS, LaCroix AZ, Barlow WE, White E, Cauley JA, Bauer DC, Weiss NS. Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States). Cancer Causes Control 2001; 12:213-22. [PMID: 11405326 DOI: 10.1023/a:1011231106772] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE This case-cohort study was designed to examine whether total hip bone mineral density (BMD) is independently associated with breast cancer over and above its association with other determinants, including levels of total and bioavailable estradiol and testosterone and sex-hormone binding globulin. METHODS Our study population was selected from a cohort of 8,203 postmenopausal women who were screened for the Fracture Intervention Trial in 1992, at which time BMD was assessed, and blood samples were obtained. A total of 109 women developed breast cancer during four years of follow-up; 173 other randomly selected women from the larger cohort were also selected. Cox proportional hazards with robust variance adjustment was used for these analyses. RESULTS Relative to women in the lower fourth of the BMD distribution, the risk associated with being in the upper fourth was 2.6 (95% confidence interval (CI) 1.1-5.8). After adjusting for serum hormone levels, the corresponding relative risk was 2.5 (95% CI 0.9-5.2). With body mass index and number of years since menopause added to the multivariate analysis, the relative risk decreased to 1.4 (95% CI 0.5-4.0). CONCLUSIONS BMD may not influence breast cancer risk independent of its relationship with endogenous hormones and measured covariates.
Collapse
Affiliation(s)
- D S Buist
- Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA.
| | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Two recent studies have shown a woman's bone mineral density (BMD) (a composite measure of exposure to many different factors throughout one's lifetime) predicts breast cancer. In a prospective cohort study, we examined whether hip BMD was associated with breast cancer risk among 8203 postmenopausal women. During an average follow-up of 3.7 years, 131 incident breast cancer cases (102 invasive) were identified. Cox proportional hazards models were used to obtain estimates of the relative risk of breast cancer. Our results demonstrate an increase in breast cancer risk among women with higher BMD. Independent of age, geographic area, and body mass index, relative to the lowest BMD quartile the risk of breast cancer (95% confidence interval) by increasing quartile was 1.9 (1.1, 3.2), 1.5 (0.8, 2.6), and 1.5 (0.8, 2.7), respectively. An examination of other factors important in determining BMD may help explain the positive association between BMD and breast cancer.
Collapse
Affiliation(s)
- D S Buist
- Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, WA 98101, USA
| | | | | | | | | |
Collapse
|
45
|
Abstract
OBJECTIVES The purpose of this study was to define how the relation between depression and self-reported physical health in patients with coronary disease is modified by other patient-centered factors. METHODS We conducted a prospective cohort study of 111 patients (members of a health maintenance organization) with angiographically documented coronary disease, examining factors (physical symptoms, psychological states and traits, and spousal support) modifying the relation between depression and patient-reported physical health 5 years later using multiple hierarchical regression models. RESULTS Five regression models (all including demographic and disease severity covariates) were constructed to predict physical health from depression only (R2 = 0.22); depression plus angina and fatigue (R2 = 0.53); depression plus positive affect and novelty seeking and their interaction (R2 = 0.48); depression plus spousal support (R2 = 0.27); and depression, angina, fatigue, positive affect, and novelty seeking (overall model) (R2 = 0.65). Depression remained significant in each model, but the proportion of variance it predicted was diminished in the presence of the other variables (bivariate r = 0.39, partial r = 0.37-0.13). CONCLUSIONS The effect of depression on self-reported physical health is significantly mediated by physical symptoms (angina and fatigue), personality states and traits (positive affect and novelty seeking), and spousal support. Positive affect and novelty seeking had more marked effects on physical health in the presence of more depression. Thus, a broad range of factors beyond the severity of coronary disease itself affect the perceived physical health of patients with coronary heart disease.
Collapse
Affiliation(s)
- M D Sullivan
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98195, USA.
| | | | | | | |
Collapse
|
46
|
Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285:906-13. [PMID: 11180734 DOI: 10.1001/jama.285.7.906] [Citation(s) in RCA: 108] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
CONTEXT Estrogens are known to be prothrombotic, and findings from the Heart and Estrogen/progestin Replacement Study suggest that in women with clinically recognized heart disease, hormone replacement therapy (HRT) may be associated with early harm and late benefit in terms of coronary events. OBJECTIVE To assess whether, as hypothesized, prothrombotic mutations modify the association between HRT use and incidence of first myocardial infarction (MI). DESIGN AND SETTING Population-based, case-control study conducted in a Seattle-based health maintenance organization. PARTICIPANTS Cases were 232 postmenopausal women aged 30 to 79 years who had their first nonfatal MI between 1995 and 1998. Controls were a stratified random sample of 723 postmenopausal women without MI who were frequency-matched to cases by age, calendar year, and hypertension status. MAIN OUTCOME MEASURE Risk of first nonfatal MI based on current use of HRT and the presence or absence of coagulation factor V Leiden and prothrombin 20210 G-->A variants among cases and controls, stratified by hypertension. RESULTS One hundred eight MI cases and 387 controls had hypertension and 124 MI cases and 336 controls did not. Among hypertensive women, the prothrombin variant was a risk factor for MI (odds ratio [OR], 4.32; 95% confidence interval [CI], 1.52-12.1) and, in this stratum, there was also a significant interaction between use of HRT and presence of the prothrombin variant on risk of MI. Compared with nonusers of HRT with wild-type genotype, women who were current users and who had the prothrombin variant (n = 8) had a nearly 11-fold increase in risk of a nonfatal MI (OR, 10.9; 95% CI, 2.15-55.2). The interaction with the prothrombin variant was more pronounced in analyses assuming 100% compliance than in those assuming 80% compliance with HRT. The interaction was absent among nonhypertensive women and was less pronounced if hypertensive and nonhypertensive women were combined into 1 group. No interaction was found for factor V Leiden in either hypertensive or nonhypertensive women. Among hypertensive women, the estimates were affected only in trivial ways by adjustment, and the interaction with the prothrombin variant was specific to HRT. CONCLUSIONS Our results suggest that among postmenopausal hypertensive women, the association between HRT use and MI risk differed between those with and without the prothrombin 20210 G-->A variant. If these findings are confirmed in other studies, screening for the prothrombin variant may permit a better assessment of the risks and benefits associated with HRT in postmenopausal women.
Collapse
Affiliation(s)
- B M Psaty
- Cardiovascular Health Research Unit, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.
| | | | | | | | | | | | | |
Collapse
|
47
|
|
48
|
Abstract
The purpose of this study was to compare biochemical markers of bone resorption and formation in young women using different hormonal contraceptive methods. Women aged 18-39 yr who were using depot medroxyprogesterone acetate (DMPA) contraception were recruited for the study; comparison women were matched by age and clinic location. There were 116 women using DMPA, 39 using oral contraceptives containing estrogen and progestin, and 72 not currently using hormonal contraceptives. Biochemical measurements were serum calcium, PTH and osteocalcin, and urine N-telopeptide. Bone density was measured using dual-energy x-ray absorptiometry. The N-telopeptide levels, adjusted for age and other risk factors, were 42.4 +/- 2.3 nmol/mmol creatinine in the DMPA group, 26.2 +/- 3.3 nmol/mmol in the oral contraceptive group, and 35.4 +/- 2.9 nmol/mmol in the nonusers; significant differences were seen in all pairwise comparisons. Osteocalcin levels showed the same pattern, although the difference between the DMPA users and nonusers was not statistically significant. There were no differences among groups in the PTH levels. The bone density at the spine was 1.086 +/- 0.085 g/cm(2) in the DMPA group, 1.103 +/- 0.095 g/cm(2) in the oral contraceptive group, and 1.093 +/- 0.090 g/cm(2) in nonusers (P = 0.051). The results suggest that in women using DMPA bone resorption exceeded bone formation.
Collapse
Affiliation(s)
- S M Ott
- Departments of Medicine, University of Washington, and the Center for Health Studies, Group Health Cooperative of Puget Sound, Seattle, Washington 98195-6426, USA
| | | | | | | | | | | |
Collapse
|
49
|
Abstract
BACKGROUND Counseling women facing the decision to initiate, continue, or discontinue hormone replacement therapy represents a major challenge for providers. Women's attitudes deserve careful consideration in this context, because attitudes may influence hormone replacement therapy use and patients' satisfaction with decision-making. Little is known about factors that may explain different attitudes. METHODS To evaluate the association between char acteristics of peri- and postmenopausal women and their attitudes toward hormone replacement therapy, we conducted a population-based, computer-assisted telephone survey of 1,076 randomly selected women, ages 50-80, at a staff-model health maintenance organization. Women with a positive or neutral attitude were compared to those with a negative attitude. We exam ined associations between attitudes and demographic and clinical characteristics, self-rated health status, physical function, personal and family history of condi tions affected by hormone replacement therapy, gyne cologic visits, provider characteristics, interactions with provider, and sources of information about hor mone replacement therapy. RESULTS The perception of being adequately informed about the benefits of hormone replacement therapy by one's provider was associated with a tripling of the likelihood of having a positive attitude toward hormone replacement therapy. Additional fac tors associated with positive attitudes included past hormone replacement therapy use, younger age, a higher level of physical functioning, and personal history of heart disease. Relationships between these vari ables and attitudes varied among current hormone replacement therapy users and nonusers. CONCLUSIONS The study findings reinforce the critical role of provider counseling in shaping women's atti tudes about hormone replacement therapy.
Collapse
Affiliation(s)
- E A Phelan
- Department of Medicine, University of Washington, Seattle, Washington, USA.
| | | | | | | | | | | |
Collapse
|
50
|
Abstract
OBJECTIVE This study examined health and behavioral risk factors for infections that required hospitalization in postmenopausal women who were enrollees of a large health maintenance organization (HMO). METHODS Participants were 1,365 generally healthy women aged 55 to 80 years who were followed for up to 6 years. Infection diagnoses listed first in the automated hospital discharge records were used to identify hospitalizations for which infections were the primary cause of admission. Potential risk factors for these serious infections were identified from baseline questionnaire information and automated HMO records from before baseline and during follow-up. Risks for infections associated with hospital admission were examined using multivariate logistic regression methods. RESULTS Seventy-three women had a total of 90 hospital admissions in which infection was the primary discharge diagnosis. Behaviors that were independent predictors of infection were physical inactivity (adj. odds ratio = 4.08; 95% CI, 1.73-9.63) and smoking (adj. odds ratio = 2.64; 95% CI, 1.11-6.26). Incident cancer and lung disease were also associated with increased risk of infection. These associations were independent of age, body mass index, functional status, and other measures of health. CONCLUSIONS Modifiable risk factors such as physical inactivity and smoking may place older women at risk for serious infections although the causal link is yet to be explained. Further research in this area may lead to new strategies aimed at reducing the serious burden of infections in the older population.
Collapse
Affiliation(s)
- S G Leveille
- Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, Maryland, USA
| | | | | | | | | | | |
Collapse
|